GlobeNewswire by notified

DSV, 997 - LAUNCH OF NEW SHARE BUYBACK PROGRAMME ACCORDING TO THE SAFE HARBOUR METHOD

Share

Company Announcement No. 997

As previously announced, the Board of Directors of DSV A/S has decided to exercise the authority to buy back shares granted by the Annual General Meeting on 17 March 2022. The authority is valid until 17 March 2027 and covers a maximum of 23,400,000 shares.

Purpose

The purpose of the share buyback is to adjust the capital structure and meet obligations relating to the Group’s share-based incentive programmes. At a General Meeting of DSV A/S, a resolution will be proposed that any shares not used for hedging or the incentive programmes will be cancelled.

Time frame

The share buyback programme will run from 15 November 2022 until 01 February 2023, both days inclusive. During this period, DSV A/S will buy own shares up to a maximum of DKK 4,000 million in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour rules.

Buyback terms

•  DSV A/S is required to retain a lead manager who is to make its own trading decisions independently of and without influence from DSV A/S and execute the buyback within the announced limits. DSV A/S has designated Nordea Bank Abp, as its lead manager for the share buyback.
•  Under the share buyback programme, DSV A/S may repurchase shares up to a maximum aggregate purchase price of DKK 4,000 million, and no more than 6,000,000 shares, corresponding to 2.56% of the current share capital of DSV A/S.
•  The shares may in no event be bought at a price deviating by more than 5 per cent from the most recently quoted market price of the shares at the time of purchase.
•  The maximum number of DSV A/S shares that may be purchased on each business day may not exceed 25% of the average daily trading volume of DSV A/S shares on Nasdaq Copenhagen during the 20 trading days preceding the date of purchase.

A company announcement of any transactions under the programme will be published every week after commencement and at the end of the programme. Any questions may be addressed to Executive Vice President, Investor Relations, Flemming Ole Nielsen, tel. +45 43 20 33 92.

Yours sincerely,
DSV A/S

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Monthly information regarding the total number of voting rights and total number of shares of the Company as of November 30, 20228.12.2022 22:30:00 CET | Press release

Monthly information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2022 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 Date Total number of sharesTotal number of voting rights11/30/2022 94,137,145 Total gross of voting rights: 94,137,145 Total net* of voting rights: 93,966,891 * Total net = total number of voting rights attached to shares – shares without voting rights Attachment PDF Version

Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants8.12.2022 22:00:00 CET | Press release

Company announcement – No. 57 / 2022 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Copenhagen, Denmark and Boston, MA, U.S. December 8, 2022 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has increased its share capital by a nominal amount of DKK 64,919 divided into 64,919 new shares with a nominal value of DKK 1 each. The increase is a consequence of the exercise of warrants granted under several of Zealand Pharma's employee warrant programs. Employee warrant programs are part of Zealand Pharma’s incentive scheme, and each warrant gives the owner the right to subscribe for one new Zealand Pharma share at a prespecified price, the exercise price, in specific predefined time periods before expiration. For a more detailed description of Zealand Pharma’s warrant programs, see the company’s Articles o

Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such8.12.2022 21:40:00 CET | Press release

COPENHAGEN, Denmark, December 8, 2022 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the company’s shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such. 1.Details of the person discharging managerial responsibilities/person closely associateda)NamePaul Chaplin2.Reason for the notificationa)Position/status President and Chief Executive Officer of Bavarian Nordic A/S b)Initial notification/AmendmentInitial notification3.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitora)NameBavarian Nordic A/Sb)LEI2138006JCDVYIN6INP514.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducteda)Description of the financial instrument, type of instrument Identification codeWarrants DK0015

Indberetning af ledende medarbejdere og disses nærtståendes transaktioner med Bavarian Nordic aktier og tilknyttede værdipapirer8.12.2022 21:40:00 CET | pressemeddelelse

KØBENHAVN, Danmark, 8. december 2022 – Bavarian Nordic A/S (OMX: BAVA) har dags dato modtaget oplysninger om følgende transaktioner med selskabets aktie/tilknyttede værdipapirer, foretaget af ledende medarbejdere og/eller personer/firmaer der er nærtstående til disse. 1.Nærmere oplysninger om personen med ledelsesansvar/personen med nær tilknytning til dennea)NavnPaul Chaplin2.Årsag til indberetningena)Stilling/titelAdministrerende direktør i Bavarian Nordic A/Sb)Første indberetning/ændringFørste indberetning3.Nærmere oplysninger om udstederen, deltageren på markedet for emissionskvoter, auktionsplatformen, auktionsholderen eller den auktionstilsynsførendea)NavnBavarian Nordic A/Sb)LEI-kode2138006JCDVYIN6INP514.Nærmere oplysninger om transaktionen/transaktionerne: gentages for i) hver type instrument, ii) hver type transaktion, iii) hver dato og iv) hvert sted, hvor der er udført transaktionera)Beskrivelse af det finansielle instrument, instrumenttypen IdentifikationskodeTegningsoption

Bavarian Nordic iværksætter nyt incitamentsprogram for koncernledelsen og udvalgte medarbejdere8.12.2022 21:35:00 CET | pressemeddelelse

KØBENHAVN, Danmark, 8. december 2022 – Bavarian Nordic A/S (OMX: BAVA) meddelte i dag, at bestyrelsen har besluttet at udstede tegningsoptioner til koncernledelsen og udvalgte medarbejdere i Bavarian Nordic koncernen. Som et nyt initiativ vil erhvervelsen (vesting) af tegningsoptioner for medlemmer af koncernledelsen være baseret på succesfuld opnåelse af relevante Key Performance Indicators (KPI’er). Beslutningen er truffet i henhold til generalforsamlingens bemyndigelser til bestyrelsen, jf. vedtægternes § 5b og 5c, og i overensstemmelse med selskabets vederlagspolitik. Der tildeles i alt 248.787 tegningsoptioner til medlemmer af koncernledelsen til en udnyttelseskurs på DKK 224,70 pr. aktie, svarende til markedskursen for Bavarian Nordics aktie på tildelingstidspunktet. Erhvervelse af tegningsoptionerne er betinget af forudgående opfyldelse af KPI’er, som fastsættes af bestyrelsen. Der tildeles i alt 683.264 tegningsoptioner til udvalgte medarbejdere i Bavarian Nordic koncernen til